Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • genetics

    regeneron headquarters

    Regeneron’s Lynozyfic granted FDA accelerated approval to treat multiple myeloma

    More than 36,000 new cases of the blood cancer are expected to be diagnosed in the US this year

    regeneron headquarters

    Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

    The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

    regeneron headquarters

    Regeneron to acquire human genetics company 23andMe for $256m

    The agreement comes two months after 23andMe filed for bankruptcy protection

    regeneron headquarters

    Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma

    More than 35,000 new cases of the blood cancer are diagnosed every year in Europe

    regeneron headquarters

    Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer

    Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year

    regeneron headquarters

    Regeneron’s odronextamab recommended by CHMP to treat certain lymphomas

    Follicular lymphoma and diffuse large B-cell lymphoma are collectively responsible for an estimated 283,000 global cases every year

    regeneron headquarters

    Regeneron and Mammoth announce gene editing partnership worth $370m per target

    The companies will aim to develop CRISPR-based therapies for multiple tissues and cell types

    regeneron headquarters

    Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol

    Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment

    regeneron headquarters

    Regeneron to acquire 2seventy’s investigational cell therapy pipeline

    An estimated 150 2seventy employees will join Regeneron’s new research and development unit

    - PMLiVE

    Survey of US oncologists highlights advanced lung cancer research gaps  

    Non-small cell lung cancer is responsible for approximately 85% of all lung cancers

    regeneron headquarters

    Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration

    The companies will develop CRISPR-based therapies for neurological and muscular diseases

    regeneron headquarters

    Regeneron’s Veopoz granted FDA approval for ultra-rare immune disease

    Fewer than ten patients in the US have been diagnosed with CHAPLE disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links